Texas Gastrointestinal Cancer Conference 2026 Financial Disclosures

Laith Abushahin reports serving on a speakers bureau/receiving honoraria for non-CME for Ipsen, Amgen, and SpringWorks Therapeutics. Laith Abushahin reports serving as a consultant/advisory board member for Revolution Medicines and Ipsen.

Daniel Ahn reports serving as a consultant/advisory board member for Exelixis, Natera, and Exact Sciences. Daniel Ahn reports the following non-mutual funds stock ownership/stock options: Lilly and Natera.

Tanios Bekaii-Saab reports receiving grant/research support from Agios, Arys, Arcus, Atreca, Boston Biomedical, Bayer, Eisai, Celgene, Lilly, Ipsen, Clovis, Seattle Genetics, Genentech, Novartis, Mirati, Merus, Abgenomics, Incyte, Pfizer, Bristol Myers Squibb, and Revolution Medicines. Tanios Bekaii-Saab reports serving as a consultant/advisory board member for AbbVie, Arcus, ArsenalBio, AstraZeneca, Bayer, BeiGene, Blueprint Medicines, Boehringer Ingelheim, Caladrius Biosciences, Celularity, Daiichi Sankyo, Deciphera, Eisai, Exact Sciences, Exelixis, FibroGen, Foundation Medicine, Genentech, GSK, Illumina, Immuneering, Imugene, Incyte, Ipsen, Janssen, Kanaph Therapeutics, Merck, Merck KGaA, Merus, Natera, Pfizer, Replimune, Revolution Medicines, Sanofi, Seattle Genetics, Servier, Sobi, Stemline Therapeutics, Suzhou Kintor Pharmaceuticals, Takeda, Treos Bio, Xilio Therapeutics, Xilis, and Zai Lab. Tanios Bekaii-Saab reports patent holder/royalties from Imugene and Recursion.

Tiago Biachi reports receiving grant/research support from Bristol Myers Squibb Foundation, AbbVie, Genmab, Ipsen, and Astellas Pharma. Tiago Biachi reports serving on a speakers bureau/receiving honoraria for non-CME for AstraZeneca. Tiago Biachi reports serving as a consultant/advisory board member for AstraZeneca, Genmab, and Delcath Systems.

Ryan Corcoran reports receiving grant/research support from Relay Therapeutics, OnKure, Parabilis Medicines, and Revolution Medicines. Ryan Corcoran reports serving as a consultant/advisory board member for AbbVie, Adcendo, Alterome Therapeutics, Bristol Myers Squibb, Cogent Biosciences, Erasca, Firefly Bio, Genentech, Nested Therapeutics, N-of-one/Qiagen, nRichDx, Parabilis Medicines, Remix Therapeutics, Revolution Medicines, Roche, Pheon Therapeutics, Sidewinder Therapeutics, and Taiho Oncology. Ryan Corcoran reports the following non-mutual funds stock ownership/stock options: Alterome Therapeutics, Proximion Therapeutics, Sidewinder Therapeutics, Avidity Biosciences, C4 Therapeutics, Cogent Biosciences, Erasca, Kinnate Biopharma, Interline Therapeutics, Nested Therapeutics, nRichDx, Pheon Therapeutics, Remix Therapeutics, and Revolution Medicines. Ryan Corcoran reports exercising stock options in Cogent, Revolution Medicines, and Erasca.

Elizabeth Cruz reports the following financial relationships: No relevant financial disclosures.

Samuel Cytryn reports serving on a speakers bureau/receiving honoraria for non-CME for Astellas Pharma, HMP Education, MJH Sciences, GI Oncology Now, and PeerView. Samuel Cytryn reports serving as a consultant/advisory board member for Amgen, Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Gilead Sciences, Henlius, and Medacorp. Samuel Cytryn reports receiving other financial or material support from GI Oncology Now.

Anthony El-Khoueiry reports receiving grant/research support from Fulgent, Auransa, AstraZeneca, and Astex. Anthony El-Khoueiry reports serving as a consultant/advisory board member for AstraZeneca, Bristol Myers Squibb, Eisai, Johnson and Johnson, AbbVie, Jazz Pharmaceuticals, Servier, Incyte, Boehringer Ingelheim, Qurient, Pfizer, and Roche/Genentech. Anthony El-Khoueiry reports receiving other financial or material support from Daiichi Sankyo.

Haley Ellis reports serving on a speakers bureau/receiving honoraria for non-CME for Incyte. Haley Ellis reports serving as a consultant/advisory board member for AstraZeneca, Cogent, and Jazz Pharmaceuticals.

Cathy Eng reports receiving grant/research support from Agenus, Amgen, Arcus, Bexion, BridgeBio (BBOT), Exelixis, Gritstone, Hutchmed, Johnson and Johnson, Pfizer, Revolution Medicines, Solstice, and Sumitomo. Cathy Eng reports serving as a consultant/advisory board member for AbbVie, Amgen, Arcus, Bristol Myers Squibb, Boehringer Ingelheim, Lilly, EMD Serono, Genmab, Gilead Sciences, GSK, Incyte, Merck, Novartis, Revolution Medicines, and Takeda. Cathy Eng reports receiving other financial or material support from Boehringer Ingelheim and Takeda.

Seth Felder reports the following non-mutual funds stock ownership/stock options: Natera stock.

Karyn Goodman reports serving as a consultant/advisory board member for GSK, RenovoRX, and Agenus.

Brian Grieb reports serving on a speakers bureau/receiving honoraria for non-CME for Revolution Medicines and AstraZeneca. Brian Grieb reports serving as a consultant/advisory board member for Pfizer, GSK, and Jazz Pharmaceuticals.

James Harding reports receiving institutional grant/research support from AbbVie, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Lilly, Incyte, Jazz Pharmaceuticals, RayzeBio, Servier, and Tvardi. James Harding reports serving as a consultant/advisory board member for Amgen, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Elevar, Exelixis, Eisai, Merck, RayzeBio, Servier, Jazz Pharmaceuticals, and Cogent.

Yelena Janjigian reports receiving institutional grant/research support from Bayer, Bristol Myers Squibb, Merck, NCI, Department of Defense, Cycle for Survival, Fred's Team, Genentech/Roche, AstraZeneca, Arcus Biosciences, Transcenta, Inspirna, Stand Up to Cancer, and Astellas Pharma. Yelena Janjigian reports serving on a speakers bureau/receiving honoraria for non-CME for Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Master Clinician Alliance, Michael J. Hennessy Associates, Merck, Research to Practice, PeerView, AbbVie, AmerisourceBergen, AskGene Pharma, Arcus Biosciences, Basilea Pharmaceutical, Bayer, Clinical Care Options, Lilly, Geneos, GSK, Guardant Health, HMP Education, Imedex, Imugene, Inspirna, Lynx Health, Pfizer, Seagen, Silverback Therapeutics, Zymeworks, Eisai, Genzyme, Ed Med Resources (OncInfo), H.C. Wainwright & Co, Physicians' Education Resource, LLC, Boehringer Ingelheim, eChinaHealth, Suzhou Liangyihui Network Technology, Talem Health, TotalCME, WebMD, BeOne, Gilead Sciences, Regeneron, IDEOlogy Health, and i3 Health. Yelena Janjigian reports serving as a consultant/advisory board member for Pfizer, Merck, Bristol Myers Squibb, Daiichi Sankyo, Bayer, Research to Practice, Imugene, AstraZeneca, Lilly, Zymeworks, Basilea Pharmaceutical, Michael J. Hennessy Associates, Paradigm, Seagen, AmerisourceBergen, Arcus Biosciences, Geneos, GSK, Imedex, Lynx Health, Silverback Therapeutics, Mersana, AskGene Pharma, AbbVie, Astellas Pharma, Guardant Health, Jazz Pharmaceuticals, Clinical Care Options, HMP Education, PeerView, Eisai, Genzyme, Ed Med Resources (OncLive), H.C. Wainwright & Co, Physicians' Education Resource, LLC, Boehringer Ingelheim, WebMD, Debbie's Dream Foundation, OncoDaily, and Signatera. Yelena Janjigian reports the following non-mutual funds stock ownership/stock options: OncoDaily.

Syed Mohammad Ali Kazmi reports receiving institutional grant/research support from Pfizer, Merck, Astellas Pharma, Lilly, and Johnson and Johnson. Syed Mohammad Ali Kazmi reports serving as a consultant/advisory board member for Taiho Oncology and Delcath. Syed Mohammad Ali Kazmi reports the following non-mutual funds stock ownership/stock options: Johnson and Johnson.

Ronan Kelly reports receiving institutional grant/research support from Bristol Myers Squibb and Lilly. Ronan Kelly reports serving on a speakers bureau/receiving honoraria for non-CME for Astellas Pharma, BeOne, and Daiichi Sankyo. Ronan Kelly reports serving as a consultant/advisory board member for Bristol Myers Squibb, Astellas Pharma, AstraZeneca, Daiichi Sankyo, Jazz Pharmaceuticals, BeOne, Gilead Sciences, Exact Sciences, Amgen, Merck, Cardinal Health, Aptitude Health, and IDEOlogy Health.

Richard Kim reports serving as a consultant/advisory board member for AstraZeneca, Elevar, Bayer, Roche, Pfizer, Takeda, AbbVie, Eisai, Exelixis, Merck, and Ipsen.

Benjamin Kitchens reports serving on a speakers bureau/receiving honoraria for non-CME for Astellas Pharma, AstraZeneca, Ipsen, Incyte, and Jazz Pharmaceuticals. Benjamin Kitchens reports serving as a consultant/advisory board member for Astellas Pharma and Incyte.

Samuel Klempner reports receiving institutional grant/research support from AstraZeneca, I-Mab, Arcus Biosciences, Mersana, Parabilis, the Torrey Coast Foundation, the Degregorio Foundation, the Gastric Cancer Foundation, Debbie's Dream Foundation, NIH/NCI, Stand Up to Cancer, and AACR. Samuel Klempner reports serving as a consultant/advisory board member for Bristol Myers Squibb, Merck, Astellas Pharma, Daiichi Sankyo, Natera, Novartis, AstraZeneca, Mersana, BeOne, Gilead Sciences, Elevation Oncology, EsoBiotec, Eisai, Taiho Oncology, Boehringer Ingelheim, I-Mab, Signet Therapeutics, and Debbie's Dream Foundation.

Pamela Kunz reports receiving institutional grant/research support from Novartis, Bristol Myers Squibb/RayzeBio, Crinetics, and Systimmune.

Eric Lander reports serving on a speakers bureau/receiving honoraria for non-CME for Natera. Eric Lander reports serving as a consultant/advisory board member for Sanofi, Tempus, Stemline, Jazz Pharmaceuticals, Bristol Myers Squibb, BeOne, and Castle Biosciences.

Seung Eun (Grace) Lee reports the following financial relationships: No relevant financial disclosures.

Michael Lidsky reports the following financial relationships: No relevant financial disclosures.

Christopher Lieu reports receiving institutional grant/research support from Janssen and Genentech. Christopher Lieu reports serving as a consultant/advisory board member for Pfizer.

Melissa Lumish reports the following financial relationships: No relevant financial disclosures.

Steven Maron reports receiving grant/research support from Conquer Cancer Foundation, AstraZeneca, 1Cell.Dx, Guardant Health, and Paige.AI. Steven Maron reports serving on a speakers bureau/receiving honoraria for non-CME for Amgen, Elevation Oncology, Purple Oncology, Voronoi, Guidepoint, and Everest Oncology. Steven Maron reports the following non-mutual funds stock ownership/stock options: stock in McKesson and options in 1Cell.Dx.

Shaun McKenzie reports serving as a consultant/advisory board member for Lexington Medical.

Rutika Mehta reports receiving grant/research support from Robert Winn CDA. Rutika Mehta reports serving as a consultant/advisory board member for Astellas Pharma, AstraZeneca, Amgen, BeOne, Bristol Myers Squibb, Jazz Pharmaceuticals, Gilead Sciences, Takeda, Legend Biotech, Replimmune, and Arcus Biosciences. Rutika Mehta reports receiving other financial or material support from Arcus Biosciences.

Michael Morse reports receiving institutional grant/research support from Exelixis, ITM, Pfizer, and Servier. Michael Morse reports serving on a speakers bureau/receiving honoraria for non-CME for Exelixis, Eisai, Incyte, Jazz Pharmaceuticals, Pfizer, and BeOne. Michael Morse reports serving as a consultant/advisory board member for Exelixis, Eisai, Incyte, and Servier.

Ryan Moy reports receiving grant/research support from Repare Therapeutics. Ryan Moy reports serving on a speakers bureau/receiving honoraria for non-CME for Curio and MDOutlook. Ryan Moy reports serving as a consultant/advisory board member for Bristol Myers Squibb, Gilead Sciences, BeOne and Amgen.

Michael Overman reports receiving grant/research support from Summit, Moma, Takeda, Roche, Lilly, Merck, Bristol Myers Squibb, Nouscom, and Phanes. Michael Overman reports serving as a consultant/advisory board member for Exelixis, Summit, GSK, Merus, 3T Biosciences, Roche, Bristol Myers Squibb, Merck, Moma, Amgen, Takeda, Pfizer, Natera, Agenus, Regeneron, and Astellas Pharma.

Wungki Park reports receiving institutional grant/research support from NIH/NCI, Break Through Cancer, Parker Institute for Cancer Immunotherapy (PICI), the Society for Immunotherapy of Cancer, the Society of MSK, Merck, Astellas Pharma, Revolution Medicines, Lepu Biopharma, Amgen, Fortvita, and Verastem Oncology. Wungki Park reports serving as a consultant/advisory board member for Astellas Pharma, Revolution Medicines, Innovent Biologics, Regeneron, KeyQuest, IMGT, Expert Connect, TD Cowen, and Guidepoint. Wungki Park reports patent holder/royalties from licensing interests related to Saccharo Inc. Wungki Park reports receiving other financial or material support from American Physician Institute, Curio, Integrity, EPICS, SignifyMD, PER, Amgen, and DAVA Oncology.

Debra Patt reports the following financial relationships: No relevant financial disclosures.

Scott Paulson reports receiving individual grant/research support from Buzzard Pharmaceuticals and institutional grant/research support from Ipsen, Bristol Myers Squibb, Exelixis, Lilly, AstraZeneca, Incyte, Deciphera, Nucana, Sotio, Camurus, Gilead Sciences, Gritstone Bio, BioNTech SE, Novartis, TransThera Biosciences, ITM Oncologics, Inspirna, Stingray Therapeutics, Revolution Medicines, and Johnson and Johnson. Scott Paulson reports being an employee/owner at Day One. Scott Paulson reports serving as a consultant/advisory board member for Bristol Myers Squibb, Ipsen, Exelixis, Pfizer, Lilly, Mirati, AstraZeneca, Novartis, Jazz Pharmaceuticals, Takeda, Seagen, Agenus, AmMax Bio, Johnson and Johnson, Amgen, and Whitehawk Therapeutics.

Meredith Pelster reports receiving institutional grant/research support from AbbVie, Accent Therapeutics, Acepodia Biotech, Affini-T Therapeutics, Agenus, Arcus Biosciences, Astellas Pharma, AstraZeneca, BeiGene, BioNTech, Boehringer Ingelheim, Chimeric Therapeutics, Coherus BioSciences, Compass Therapeutics, CytomX, Daiichi Sankyo, DynamiCure Biotechnology, Elevation Oncology, Elicio Therapeutics, Fate Therapeutics, Fog Pharmaceuticals, Frontier Medicines, GSK, HiberCell, Immune-Onc Therapeutics, Impact Therapeutics, Institut de Recherches Internationales Servier, Ipsen, Janssen, Jazz Pharmaceuticals, Kura Oncology, Leap Therapeutics, Marengo Therapeutics, MediLink Therapeutics, Panbela Therapeutics, Quanta Therapeutics, Recursion Pharmaceuticals, Renovo, Revolution Medicines, Roche, Seagen, SQZ Biotechnologies, Tachyon Therapeutics, Takeda, TORL Biotherapeutics, TransThera Sciences, ZielBio, and 1200 Pharma. Meredith Pelster reports serving as a consultant/advisory board member for ADC Therapeutics, BeOne, BicycleTx, BioNTech, Bristol Myers Squibb, Curio Science, CytomX, Genentech/Roche, Immunome, Kura Oncology, Normunity, Novocure, Onviv, Pfizer, Revolution Medicines, and Takeda.

Philip A Philip reports receiving grant/research support from Amgen, BioNTech, Bristol Myers Squibb, GE, Panbela, Taiho Oncology, Novartis, and Revolution Medicines. Philip A Philip reports serving on a speakers bureau/receiving honoraria for non-CME for Revolution Medicines, Exact Sciences, and Novocure. Philip A Philip reports serving as a consultant/advisory board member for Novocure, BioNTech, Corcept, Curio, Incyte, Oncolytics, Boston Pharma, Ipsen, Jazz Pharmaceuticals, Exact Sciences, and Natera. Philip A Philip reports receiving other financial or material support from Oncolytics.

Nikolaus Schultz reports serving on a speakers bureau/receiving honoraria for non-CME for AstraZeneca.

Shiraj Sen reports serving on a speakers bureau/receiving honoraria for non-CME for Guardant Health. Shiraj Sen reports serving as a consultant/advisory board member for Revolution Medicines and Bayer Pharmaceuticals.

Darshil Shah reports receiving grant/research support from Amgen, Revolution Medicines, and AstraZeneca. Darshil Shah reports serving on a speakers bureau/receiving honoraria for non-CME for Jazz Pharmaceuticals. Darshil Shah reports serving as a consultant/advisory board member for Pfizer, Bristol Myers Squibb, Incyte, Gilead Sciences, Revolution Medicines, Ipsen, Tempus AI, BeOne, and AstraZeneca.

Hollie Sheffield reports the following financial relationships: No relevant financial disclosures.

Neeta Somaiah reports receiving grant/research support from AstraZeneca, Bayer, IDRX, GSK, Deciphera, Cogent, Ningo Newbay, Ascentage, and Aadi Biosciences. Neeta Somaiah reports serving as a consultant/advisory board member for EMD Serono, Cogent, Natera, and Ipsen.

Zsofia Stadler reports intellectual property rights in SOPHiA Genetics. Zsofia Stadler reports serving as Editor-in-Chief for JCO Precision Oncology and as a section editor for UpToDate. Zsofia Stadler reports that an immediate family member is Co-Founder, CMO, and President of Blue Gen Therapeutics Foundation and serves as an ophthalmology consultant for Beacon Therapeutics, Capsida, Lilly, and Regeneron Pharmaceuticals.

Margaret Tempero reports receiving grant/research support from GRAIL-REACH Trial. Margaret Tempero reports serving on a speakers bureau/receiving honoraria for non-CME for Bristol Myers Squibb. Margaret Tempero reports serving as a consultant/advisory board member for UCSF, Astellas Pharma, Merck, Bristol Myers Squibb, RenovoRX, Urogen, Global Bio Fund, AstraZeneca, Immunovia, Regeneron, CytomX Therapeutics, and Binaytara.

Nataliya Uboha reports receiving grant/research support from Ipsen, Gilead Sciences, and Arcus. Nataliya Uboha reports serving as a consultant/advisory board member for Jazz Pharmaceuticals, Bristol Myers Squibb, Merck, BeOne, Gilead Sciences, Arcus, Eisai, Leap Therapeutics, Astellas Pharma, AstraZeneca, Daiichi Sankyo, Natera, Novocure, Radionetics Oncology, and Bayer. Nataliya Uboha reports receiving other financial or material support from Astellas Pharma.

Mark Yarchoan reports receiving institutional grant/research support from Bristol Myers Squibb, Genentech, and Incyte. Mark Yarchoan reports serving on a speakers bureau/receiving honoraria for non-CME for AstraZeneca, Genentech, Incyte, Boehringer Ingelheim, Boston Scientific, and Bristol Myers Squibb. Mark Yarchoan reports the following non-mutual funds stock ownership/stock options: Adventris Pharmaceuticals. Mark Yarchoan reports patent holder/royalties from Adventris Pharmaceuticals.